Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF - PHASE2 - RECRUITING
ongoing trials trial from www.clinicaltrials.gov
Details- 2024
- Kors van der Ent
Bionic Pancreas in CFRD - PHASE3 - NOT_YET_RECRUITING
ongoing trials trial from www.clinicaltrials.gov
Details- 2024
- Jaeb Center for Health Research
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People With Cystic Fibrosis - Phase 1|Phase 2 - Recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2023
- Cystetic Medicines, Inc.|DevPro Biopharma
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis - - RECRUITING
ongoing trials trial from www.clinicaltrials.gov
Details- 2024
Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study - - NOT_YET_RECRUITING
ongoing trials trial from www.clinicaltrials.gov
Details- 2024
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes - Phase 2|Phase 3 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2023
- Amir Moheet|University of Minnesota
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2023
- Clarametyx Biosciences, Inc.
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairaflyâ¢) - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2023
- Boehringer Ingelheim
Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis - Phase 4 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2023
- Johns Hopkins University|Cystic Fibrosis Foundation
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2022
- Aceragen